Evidence map›Paper›PMID 28288641›Full record

ArticleMolecular cancer2017

SOX2 regulates multiple malignant processes of breast cancer development through the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis.

Kuancan Liu, Fuan Xie, Anding Gao, Rui Zhang, Long Zhang, Zhangwu Xiao, Qiong Hu, Weifeng Huang, Qiaojia Huang, Baoshun Lin and 4 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 101 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Expert opinion on therapeutic targets · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Role of miR‑181a‑5p in cancer (Review).International journal of oncology · 2023
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Kuancan LiuInstitute for Laboratory Medicine, Fuzhou General Hospital, PLA, Fuzhou, 350025, Fujian, People's Republic of China. Liukuancan@163.com.
Fuan XieInstitute for Laboratory Medicine, Fuzhou General Hospital, PLA, Fuzhou, 350025, Fujian, People's Republic of China.
Anding GaoInstitute for Laboratory Medicine, Fuzhou General Hospital, PLA, Fuzhou, 350025, Fujian, People's Republic of China.
Rui ZhangInstitute for Laboratory Medicine, Fuzhou General Hospital, PLA, Fuzhou, 350025, Fujian, People's Republic of China.
Long ZhangLife Science Institute, Zhejiang University, Hangzhou, 310058, Zhejiang, People's Republic of China.
Zhangwu XiaoEmergency Department of the 476 Hospital, Fuzhou General Hospital, PLA, Fuzhou, 350002, Fujian, People's Republic of China.
Qiong HuDong fang Hospital, Xiamen University, Fuzhou, 350025, Fujian, People's Republic of China.
Weifeng HuangMedical College, China Three Gorges University, Yichang, 443002, Hubei, People's Republic of China.
Qiaojia HuangInstitute for Laboratory Medicine, Fuzhou General Hospital, PLA, Fuzhou, 350025, Fujian, People's Republic of China.
Baoshun LinInstitute for Laboratory Medicine, Fuzhou General Hospital, PLA, Fuzhou, 350025, Fujian, People's Republic of China.
Jian ZhuDepartment of Microbiology and Immunology, University of Rochester, Rochester, 14642, NY, USA.
Haikun WangInstitute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, People's Republic of China.
Jianwen QueDepartment of Medicine, Columbia University Medical Center, New York, 10032, NY, USA. jq2240@cumc.columbia.edu.
Xiaopeng LanInstitute for Laboratory Medicine, Fuzhou General Hospital, PLA, Fuzhou, 350025, Fujian, People's Republic of China. Lanxp@sina.com.
Fuzhou General Hospital of Nanjing Military Command · CNXiamen University · CNChina Three Gorges University · CNChinese Academy of Sciences · CNColumbia University Irving Medical Center · USFujian Medical University · CNUniversity of Rochester · USZhejiang University · CN

Funding

Basal Progenitor Cells and Eosinophilic EsophagitisR01DK100342 · NIDDK · UNIVERSITY OF ROCHESTER · PI QUE, JIANWEN · 2014 to 2022
$3.3M
Investigation of Latency Promoting Genes (LPGs) in HIV Oral Reservoir CellsR01DE025447 · NIDCR · UNIVERSITY OF ROCHESTER · PI ZHU, JIAN · 2015 to 2019
$1.9M
NIDCR NIH HHS R01 DE025447NIDDK NIH HHS R01 DK100342
6 · The paper itself

Abstract

backgroundHigh levels of SOX2 protein are correlated with increased dissemination of breast cancer. However, the underlying molecular mechanisms are not fully understood.

methodsIn this study we investigate the role of SOX2 in breast cancer metastasis using multiple in vitro and in vivo assays including cell culture, shRNA-mediated knockdown, wound healing, colony formation, transwell chamber, xenograft and tail vein injection. Moreover, western blot, immunostaining, microarray and real-time PCR were used to determine the change of protein and miRNA levels. Luciferase assays were also used to evaluate activity which TUSC3 is a target of miR-181a-5p and miR-30e-5p, and the clinical survival relevance was analyzed by Kaplan-Meier analysis.

resultsWe identified a novel pathway involving SOX2 regulation of microRNAs to control the proliferation and migration of breast cancer cells. shRNA-mediated knockdown of SOX2 inhibits breast cancer cell expansion and migration. More importantly, we found that these changes are accompanied by significant reduction in the levels of two microRNAs, miR-181a-5p and miR-30e-5p. Overexpression of these two microRNAs leads to reduced protein levels of Tumor Suppressor Candidate 3 (TUSC3) in breast cancer cells; mutations of the potential binding sites in the 3'-UTR of TUSC3 abrogate the inhibitory effects of the microRNAs. We further found that upregulation of TUSC3 expression leads to reduced proliferation and migration of breast cancer cells. In human breast cancer samples the levels of TUSC3 protein are inversely correlated with those of SOX2 protein.

conclusionsTaken together, our work reveals a novel SOX2-mediated regulatory axis that plays critical roles in the proliferation, migration and invasiveness of breast cancer cells. Targeting this axis may provide beneficial effect in the treatment of breast cancer.

Indexed as

Gene Expression Regulation, NeoplasticRNA InterferenceAnimalsBreast NeoplasmsCell Line, TumorCell MovementCell ProliferationDisease Models, AnimalDisease ProgressionFemaleGene Knockdown TechniquesHeterograftsHumansKaplan-Meier EstimateMembrane ProteinsMiceMembrane ProteinsMicroRNAsMIRN-181 microRNA, humanMIRN30b microRNA, humanSOX2 protein, humanSOXB1 Transcription FactorsTumor Suppressor ProteinsTUSC3 protein, humanBreast cancermiRNASox2Tumourigenesis

Identifiers

PMID28288641
PMCPMC5348847
OpenAlexW2595718592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.